Showing 221-230 of 440 results for "".
- Annual Aesthetic Society Survey: Plastic Surgery Procedures Rose by 14% in 2022https://modernaesthetics.com/news/annual-aesthetic-society-survey-plastic-surgery-procedures-rose-by-14-in-2022/2473474/There was a 14% increase in total aesthetic procedures, largely attributed to the soaring popularity of nonsurgical procedures in 2022, according to the latest statistics from the Aesthetic Society. Nonsurgical procedures jumped by 23% last year, the data show. "The lands
- Merz Aesthetics Named Sole Distributor of AccuVein’s Visualization Systemhttps://modernaesthetics.com/news/merz-aesthetics-named-sole-distributor-of-accuveins-visualization-system/2473439/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio ad
- FDA Clears Renuvion APR Handpiece for Coagulation of Subcutaneous Soft Tissues after Liposuction for Body Contouringhttps://modernaesthetics.com/news/fda-clears-renuvion-apr-handpiece-for-coagulation-of-subcutaneous-soft-tissues-after-liposuction-for-body-contouring/2473404/The U.S. Food and Drug Administration (FDA) cleared the Renuvion APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring. “The Renuvion APR handpiece is the only device to have a 510(k)
- Dr. Melinda Haws Named New Aesthetic Society Presidenthttps://modernaesthetics.com/news/dr-melinda-haws-named-new-aesthetic-society-president/2473398/Nashville, Tenn.-based plastic surgeon Melinda Haws, MD is the new president of the Aesthetic Society and the s
- Binge Watch Alert: The Aesthetic Society Drops New Episodes of Beyond the Before & Afterhttps://modernaesthetics.com/news/binge-watch-alert-the-aesthetic-society-drops-new-episodes-ofbeyond-the-before-after/2473389/The Aesthetic Society dropped four new episodes of their original docuseries 'Beyond the
- U.S. FDA Clears Renuvion to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissuehttps://modernaesthetics.com/news/fda-clears-of-renuvion-to-coagulate-and-contract-soft-tissues-including-subcutaneous-tissue/2473371/The U.S. Food and Drug Administration (FDA) has cleared the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. (Soft tissue includes subcutaneous tissue.) “We are pleas
- U.S. FDA Gives Nod to Sofwave’s SUPERB Technology for Cellulite Improvementhttps://modernaesthetics.com/news/us-fda-gives-nod-to-sofwaves-superb-technology-for-cellulite-improvement/2473342/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology employs cooled transducers that are directly coupled to the epidermis, creating a unique
- Aesthetics Biomedical Inc. Scores Third U.S. Patent for SoME Skincarehttps://modernaesthetics.com/news/aesthetics-biomedical-inc-scores-third-us-patent-for-some-skincare/2473277/Aesthetics Biomedical Inc. scored its third U.S. patent for “biological preserving composition and methods of use” for its SoME skincare product line. The patent covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME Skincar
- Coming Soon: An Increased Demand for Plus-Sized Body Contouring Procedureshttps://modernaesthetics.com/news/coming-soon-an-increased-demand-for-plus-sized-body-contouring-procedures/2473266/Plus size models have gained in popularity in the fashion business and on social media, and plastic surgeons will likely see an increased demand for procedures that enhance the plus size body type, according to researchers from Boston University School of Medicine (BUSM).
- Bausch Health Suspends Plans for Solta IPOhttps://modernaesthetics.com/news/bausch-health-suspends-plans-for-solta-ipo-1/2473255/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a